Entering text into the input field will update the search result below

Merck draws mixed views on Street despite backing from FDA panel for COVID-19 pill

Dec. 01, 2021 9:29 AM ETMerck & Co., Inc. (MRK)PFEBy: Dulan Lokuwithana, SA News Editor3 Comments

Merck & Co. headquarters in Silicon Valley

Sundry Photography/iStock Editorial via Getty Images

  • Merck (NYSE:MRK) is trading flat in the pre-market after narrowly winning the support of an FDA advisory panel on Tuesday for the company’s oral COVID-19 therapy molnupiravir for use in high-risk adults.
  • Commenting

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.